These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10722479)

  • 41. Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants.
    Okuda J; Hayakawa E; Nishibuchi M; Nishino T
    Antimicrob Agents Chemother; 1999 May; 43(5):1156-62. PubMed ID: 10223929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.
    Li Z; Deguchi T; Yasuda M; Kawamura T; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3293-5. PubMed ID: 9835531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
    Pestova E; Millichap JJ; Noskin GA; Peterson LR
    J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.
    Millichap JJ; Pestova E; Siddiqui F; Noskin GA; Peterson LR
    J Clin Microbiol; 2001 Jul; 39(7):2719-21. PubMed ID: 11427605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
    Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
    Mouneimné H; Robert J; Jarlier V; Cambau E
    Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
    Urban C; Rahman N; Zhao X; Mariano N; Segal-Maurer S; Drlica K; Rahal JJ
    J Infect Dis; 2001 Sep; 184(6):794-8. PubMed ID: 11517444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.
    Zheng X; Johnson C; Lu Y; Yanagihara R; Hollingshead S; Crain M; Benjamin W; Waites KB
    Int J Antimicrob Agents; 2001 Oct; 18(4):373-8. PubMed ID: 11691571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
    Jones ME; Sahm DF; Martin N; Scheuring S; Heisig P; Thornsberry C; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 2000 Feb; 44(2):462-6. PubMed ID: 10639387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.
    Kanematsu E; Deguchi T; Yasuda M; Kawamura T; Nishino Y; Kawada Y
    Antimicrob Agents Chemother; 1998 Feb; 42(2):433-5. PubMed ID: 9527801
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Kawamura T; Takahashi Y; Okezaki E; Nagata O; Kato H; Kawada Y
    J Antimicrob Chemother; 1997 Dec; 40(6):907-9. PubMed ID: 9462448
    [No Abstract]   [Full Text] [Related]  

  • 55. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
    Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
    Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis.
    Yokoi S; Yasuda M; Ito S; Takahashi Y; Ishihara S; Deguchi T; Maeda S; Kubota Y; Tamaki M; Fukushi H
    J Infect Chemother; 2004 Oct; 10(5):262-7. PubMed ID: 16163459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
    Bast DJ; Low DE; Duncan CL; Kilburn L; Mandell LA; Davidson RJ; de Azavedo JC
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3049-54. PubMed ID: 11036021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.